These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Westeneng HJ; Debray TPA; Visser AE; van Eijk RPA; Rooney JPK; Calvo A; Martin S; McDermott CJ; Thompson AG; Pinto S; Kobeleva X; Rosenbohm A; Stubendorff B; Sommer H; Middelkoop BM; Dekker AM; van Vugt JJFA; van Rheenen W; Vajda A; Heverin M; Kazoka M; Hollinger H; Gromicho M; Körner S; Ringer TM; Rödiger A; Gunkel A; Shaw CE; Bredenoord AL; van Es MA; Corcia P; Couratier P; Weber M; Grosskreutz J; Ludolph AC; Petri S; de Carvalho M; Van Damme P; Talbot K; Turner MR; Shaw PJ; Al-Chalabi A; Chiò A; Hardiman O; Moons KGM; Veldink JH; van den Berg LH Lancet Neurol; 2018 May; 17(5):423-433. PubMed ID: 29598923 [TBL] [Abstract][Full Text] [Related]
11. Brain Plasticity Modulator p75 Neurotrophin Receptor in Human Urine after Different Acute Brain Injuries-A Prospective Cohort Study. Hellström S; Sajanti A; Srinath A; Bennett C; Girard R; Cao Y; Frantzén J; Koskimäki F; Falter J; Lyne SB; Rantamäki T; Takala R; Posti JP; Roine S; Puolitaival J; Jänkälä M; Kolehmainen S; Rahi M; Rinne J; Castrén E; Koskimäki J Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255217 [TBL] [Abstract][Full Text] [Related]
12. Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence? Jourdi G; Fleury S; Boukhatem I; Lordkipanidzé M Neural Regen Res; 2024 Mar; 19(3):536-541. PubMed ID: 37721281 [TBL] [Abstract][Full Text] [Related]
13. Neurotrophic factors in the physiology of motor neurons and their role in the pathobiology and therapeutic approach to amyotrophic lateral sclerosis. Stansberry WM; Pierchala BA Front Mol Neurosci; 2023; 16():1238453. PubMed ID: 37692101 [TBL] [Abstract][Full Text] [Related]
14. Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications. Sanchez-Tejerina D; Llaurado A; Sotoca J; Lopez-Diego V; Vidal Taboada JM; Salvado M; Juntas-Morales R Cells; 2023 Apr; 12(8):. PubMed ID: 37190090 [TBL] [Abstract][Full Text] [Related]
15. Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75 Fleury S; Schnitzer ME; Ledoux-Hutchinson L; Boukhatem I; Bélanger JC; Welman M; Busseuil D; Tardif JC; D'Antono B; Lordkipanidzé M Front Aging Neurosci; 2022; 14():821865. PubMed ID: 35264944 [TBL] [Abstract][Full Text] [Related]
16. Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Katzeff JS; Bright F; Phan K; Kril JJ; Ittner LM; Kassiou M; Hodges JR; Piguet O; Kiernan MC; Halliday GM; Kim WS Brain; 2022 Jun; 145(5):1598-1609. PubMed ID: 35202463 [TBL] [Abstract][Full Text] [Related]
17. Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75 Simmons DA; Mills BD; Butler Iii RR; Kuan J; McHugh TLM; Akers C; Zhou J; Syriani W; Grouban M; Zeineh M; Longo FM Neurotherapeutics; 2021 Apr; 18(2):1039-1063. PubMed ID: 33786806 [TBL] [Abstract][Full Text] [Related]
18. Peripheral Glycolysis in Neurodegenerative Diseases. Bell SM; Burgess T; Lee J; Blackburn DJ; Allen SP; Mortiboys H Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255513 [TBL] [Abstract][Full Text] [Related]
19. Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant). Vucic S; Ryder J; Mekhael L; Rd H; Mathers S; Needham M; Dw S; Mc K; Medicine (Baltimore); 2020 Feb; 99(6):e18904. PubMed ID: 32028398 [TBL] [Abstract][Full Text] [Related]